Meeting
2023 ASCO Annual Meeting
Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.
Authors
Manmeet Singh Ahluwalia
Miami Cancer Institute, Baptist Health South Florida, Miami, FL
Manmeet Singh Ahluwalia , Ahmad Ozair , Atulya Aman Khosla , Yasmeen Rauf , Wei Wei , Erin Sennett Murphy , Samuel T. Chao , John H. Suh , Glen Stevens , David M. Peereboom
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03514069
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2060)
DOI
10.1200/JCO.2023.41.16_suppl.2060
Abstract #
2060
Poster Bd #
417
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.
First Author: Yasmeen Rauf
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
First Author: Howard Colman
Poster
2022 ASCO Annual Meeting
Phase 1 trial of ruxolitinib, temozolomide, and radiation in high-grade gliomas.
First Author: Manmeet Singh Ahluwalia
Poster
2022 ASCO Annual Meeting
Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).
First Author: Louis B. Nabors